

Analysis of the full genome sequences of SARS-CoV-2 isolates to determine antigenic proteins and epitopes to be used for the development of a vaccine or a diagnostic approach for COVID-19

Hüseyin Can¹, Ahmet Efe Köseoğlu¹, Sedef Erkunt Alak¹, Mervenur Güvendi¹, Mert Döşkaya², Muhammet Karakavuk³, Adnan Yüksel Gürüz², Cemal Ün^{1,*}

¹Ege University Faculty of Science Department of Biology Molecular Biology Section, İzmir, Turkey

²Ege University Faculty of Medicine Department of Parasitology, İzmir, Turkey

³Ege University, Ödemiş Vocational School, İzmir, Turkey

Supplementary 1. Accession numbers of SARS-COV-2 isolates used in this study.

Country	Accession Number
China-Wuhan (SARS-CoV2)	NC_045512
China-Yunnan	MT049951
South Korea	MT039890
India	MT050493
Japan	LC528233
Pakistan	MT240479
Brazil	MT126808
Italy	MT066156
Spain	MT198653
Sweden	MT093571
Finland	MT020781
Turkey	EPI_ISL_424366
Singapore	EPI_ISL_414379
England	EPI_ISL_420910
Germany	EPI_ISL_419552
Greece	EPI_ISL_418263
Greece	EPI_ISL_418264
France	EPI_ISL_420625
USA-Texas	EPI_ISL_420798
USA-New York	EPI_ISL_420793
USA-Washington	EPI_ISL_419555
Canada-British Colombia	EPI_ISL_418859
Canada-Ontario	EPI_ISL_418384
Georgia	EPI_ISL_420140
Georgia	EPI_ISL_420144
Kuwait	EPI_ISL_416541
Kuwait	EPI_ISL_416458
Argentina	EPI_ISL_420600
Colombia	EPI_ISL_418262
Chile	EPI_ISL_415661
Ecuador	EPI_ISL_417482
Australia-Western Australia	EPI_ISL_420539
Australia-Queensland	EPI_ISL_420879
Australia-Northern Territory	EPI_ISL_419833
Australia-Victoria	EPI_ISL_420876
New Zealand	EPI_ISL_416538
Senegal	EPI_ISL_420079
Algeria	EPI_ISL_418241
South Africa	EPI_ISL_417186
Congo	EPI_ISL_420854
Nigeria	EPI_ISL_413550